Co-blockade of Immune Checkpoints and Adenosine A Receptor Suppresses Metastasis

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2015 May 6

PMID 25941583

Citations 13

Authors

Arabella Young

Deepak Mittal

Kimberley Stannard

Michelle Yong

Michele Wl Teng

Bertrand Allard

John Stagg

Mark J Smyth

Affiliations

Soon will be listed here.

Abstract

Immunosuppressive pathways active within the tumor microenvironment must be targeted in combination to sufficiently bolster antitumor immune defenses. Inhibition of A adenosine receptor signaling in combination with immune checkpoint blockade enhances CD8 T and NK cell anti-metastatic activity. This results in reduced metastatic burden and improved survival in pre-clinical models.

Citing Articles

Chemobrain: An accelerated aging process linking adenosine A receptor signaling in cancer survivors.

Oliveros A, Poleschuk M, Cole P, Boison D, Jang M Int Rev Neurobiol. 2023; 170:267-305.

PMID: 37741694 PMC: 10947554. DOI: 10.1016/bs.irn.2023.08.003.

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Xu S, Wang C, Yang L, Wu J, Li M, Xiao P Front Immunol. 2023; 14:1199631.

PMID: 37313405 PMC: 10258331. DOI: 10.3389/fimmu.2023.1199631.

Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A Receptor with Preladenant Conjugates.

Claff T, Klapschinski T, Tiruttani Subhramanyam U, Vaassen V, Schlegel J, Vielmuth C Angew Chem Int Ed Engl. 2022; 61(22):e202115545.

PMID: 35174942 PMC: 9310709. DOI: 10.1002/anie.202115545.

Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy.

Cheng P, Shen P, Shan Y, Yang Y, Deng R, Chen W Front Cell Dev Biol. 2021; 9:626045.

PMID: 34568308 PMC: 8455814. DOI: 10.3389/fcell.2021.626045.

Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?.

Ben-Shmuel A, Biber G, Barda-Saad M Front Immunol. 2020; 11:275.

PMID: 32153582 PMC: 7046808. DOI: 10.3389/fimmu.2020.00275.

References

Ohta A, Gorelik E, Prasad S, Ronchese F, Lukashev D, Wong M . A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006; 103(35):13132-7. PMC: 1559765. DOI: 10.1073/pnas.0605251103. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Mittal D, Young A, Stannard K, Yong M, Teng M, Allard B . Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014; 74(14):3652-8. DOI: 10.1158/0008-5472.CAN-14-0957. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Allard B, Pommey S, Smyth M, Stagg J . Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013; 19(20):5626-35. DOI: 10.1158/1078-0432.CCR-13-0545. View